{
    "id": 12654,
    "fullName": "RET A883F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RET A883F lies within the protein kinase domain of the Ret protein (UniProt.org). A883F confers a gain of function to the Ret protein as demonstrated by increased Ret kinase activity (PMID: 24561444) and is transforming in cell culture (PMID: 10445857, PMID: 10679286).",
            "references": [
                {
                    "id": 3686,
                    "pubMedId": 24561444,
                    "title": "RET revisited: expanding the oncogenic portfolio.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24561444"
                },
                {
                    "id": 2268,
                    "pubMedId": 10445857,
                    "title": "Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10445857"
                },
                {
                    "id": 11578,
                    "pubMedId": 10679286,
                    "title": "A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10679286"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "A883F",
    "createDate": "10/01/2015",
    "updateDate": "07/02/2018",
    "referenceTranscriptCoordinates": {
        "id": 125151,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43120120_43120121delGCinsTT",
        "cDna": "c.2647_2648delGCinsTT",
        "protein": "p.A883F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3420,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET A883F in culture (PMID: 15184865).",
            "molecularProfile": {
                "id": 12807,
                "profileName": "RET A883F"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3687,
                    "pubMedId": 15184865,
                    "title": "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15184865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3224,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET A883F in culture (PMID: 23526464).",
            "molecularProfile": {
                "id": 12807,
                "profileName": "RET A883F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 12807,
            "profileName": "RET A883F",
            "profileTreatmentApproaches": [
                {
                    "id": 6914,
                    "name": "RET Inhibitor",
                    "profileName": "RET A883F"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 125152,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43120120_43120121delGCinsTT",
            "cDna": "c.2647_2648delGCinsTT",
            "protein": "p.A883F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 125151,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43120120_43120121delGCinsTT",
            "cDna": "c.2647_2648delGCinsTT",
            "protein": "p.A883F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}